Two-Drug combo aims to tackle Hard-to-Treat hodgkin lymphoma
NCT ID NCT04510636
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial tests whether combining pembrolizumab (Keytruda) with bendamustine (Treanda) is safe and effective for people with Hodgkin lymphoma that has come back or is no longer responding to standard treatments. About 40 adults will receive the drug combination, and researchers will measure how many achieve a complete or partial response using PET/CT scans. The goal is to see if this two-drug approach can shrink or eliminate cancer in this difficult-to-treat group.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- pembrolizumab (Keytruda) and bendamustine (Treanda)
- What this could lead to
- If successful, this combination could offer a new treatment option for people with Hodgkin lymphoma that has returned or stopped responding to standard therapy.
- What could go wrong
- This is a small, early-phase study (40 participants) without a comparison group, so results may not be definitive. Side effects from the drug combination could be significant.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CLASSICAL HODGKIN LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Princess Margaret Cancer Centre
RECRUITINGToronto, Ontario, M5G 2M9, Canada
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new nucleotide analogue boost cancer treatment?
- Can a drug duo outsmart resistant lymphomas?
- Immunotherapy may let some hodgkin lymphoma patients avoid intensive chemo and radiation
- New drug combo aims to tackle Hard-to-Treat hodgkin lymphoma
- Engineered donor cells take on lymphoma in early trial
- New hope for kids with lymphoma: drug combo may replace harsh chemo